Strata Critical Medical (SRTA) – Q4 2025 results and 2026 guidance after the Blade rebrand

Strata Critical Medical is now a focused time-critical logistics and medical services provider for the U.S. transplant system, after selling its passenger division to Joby Aviation and rebranding from Blade Air Mobility (BLDE) to SRTA in August 2025. The core idea is simple: a one-call, integrated solution that combines air and ground logistics, surgical organ recovery, organ placement and specialized perfusion services for cardiovascular surgery.

The company operates one of the largest dedicated organ transport and surgical services networks in the United States, serving transplant hospitals and Organ Procurement Organizations (OPOs). The Keystone acquisition brought perfusion staffing and equipment for cardiovascular centers under the same umbrella, creating a two-segment structure:

• Logistics – aircraft and ground transport for organs and surgical teams, plus coordination of complex multi-leg transplant missions. This is Strata’s legacy core business and still represents the majority of revenue.
• Clinical – transplant clinical services and perfusion for cardiovascular surgery, grouped under the Trinity Medical Solutions and Keystone Perfusion brands. This segment is newer, higher-margin and strategically important for deepening the relationship with hospitals.

Regulators are tightening performance expectations for OPOs and transplant centers, especially around Donation after Circulatory Death (DCD) and better utilization of marginal organs. Management explicitly frames this as a structural tailwind for Strata: high-performing OPOs and transplant centers tend to outsource complex logistics and organ recovery to specialized providers, and Strata is positioning itself as a partner of choice for these “gold standard” institutions.

Q4 2025 is the company’s first full quarter after Keystone’s mid-September acquisition and shows what the combined platform can deliver: strong top-line growth, improving gross margins and positive Adjusted EBITDA, offset by still-meaningful GAAP losses and negative free cash flow.

Total revenue reached $66.8M, up 83.5% year-over-year, while gross profit nearly doubled to $14.4M. The gross margin expanded by approximately 80 basis points to 21.6%, driven by a mix of higher-margin clinical revenue from Keystone and improved logistics margins. On a segment basis:

• Logistics revenue grew 35.3% to $49.2M, representing the company’s organic growth engine, supported by new and existing customers and a higher attachment rate for logistics on transplant clinical cases.
• Clinical revenue reached $17.6M versus $2.8M in Q3 2025, reflecting the first full quarter of Keystone. Within clinical, transplant clinical revenue was $7.8M and other clinical revenue $9.8M.

Selling, general and administrative expenses increased less than revenue but still weighed on profits: SG&A rose 46.9% year-over-year in Q4 to $19.3M, while amortization of intangibles rose with the acquired Keystone assets. The operating loss from continuing operations widened slightly to $(6.4)M, but the net loss from continuing operations improved to $(5.4)M versus $(7.4)M a year earlier, thanks in part to stronger gross profit and lower interest expense after the portfolio reshaping.

For the full year 2025, Strata delivered $197.1M in revenue (up 34.3% vs. 2024) and $41.1M in gross profit (up 39%). Adjusted EBITDA reached $14.1M, beating the high end of the guidance range, for a 7.1% Adjusted EBITDA margin. GAAP net loss from continuing operations was $(20.1)M, larger than the $(16.2)M loss in 2024, reflecting integration costs, amortization and non-recurring items.

Cash flow remains the main weak spot: Q4 2025 operating cash flow was $(8.3)M, with a $15.3M gap versus Adjusted EBITDA due to a legacy legal settlement, residual transaction costs and working capital build-up. Free cash flow from continuing operations before aircraft and engines was $(8.7)M for the quarter. Capital expenditures of $2M were driven primarily by aircraft maintenance and logistics vehicle purchases.

Heading into 2026, Strata combines a clean balance sheet with a more ambitious guidance framework and a dedicated credit facility to support bolt-on acquisitions. This is the core of the investment case: compound growth in a regulated niche, financed primarily through organic cash generation and targeted M&A.

At year-end 2025, the company reported $61.2M in cash and short-term investments, with a very modest Debt/Equity ratio of 0.01 and a quick and current ratio of 4.39×. In early February 2026, Strata also closed a $30M asset-backed credit facility with JP Morgan, which is currently undrawn and can be upsized to $50M subject to conditions. The facility is explicitly tied to the M&A pipeline, effectively pre-funding future acquisitions without heavy equity dilution, at least in the near term.

On the outlook side, management raised its 2026 revenue guidance to $260–275M (from $255–270M) and Adjusted EBITDA guidance to $29–33M (from $28–32M). It also guided to free cash flow before aircraft and engine acquisitions of $15–22M. This implies continued margin expansion and a significant improvement in cash generation versus 2025, assuming integration and pricing execution remain on track.

The key question for investors is whether the company can consistently convert Adjusted EBITDA into free cash flow while funding maintenance capex and selective aircraft/vehicle additions. The undrawn JP Morgan facility provides flexibility, but the market will scrutinize leverage discipline and return on invested capital as the M&A program accelerates.

Ownership, sell-side coverage and retail participation all matter for a relatively small, high-beta name like SRTA. Here the picture is mixed but constructive: insiders hold a meaningful stake, long-only institutions are present, and there is non-trivial short interest reflecting debate on execution and valuation.

For an execution-driven, small-cap services platform like Strata, the investment debate is naturally split between a bullish view on structural transplant growth and a bearish view on cash-flow and integration risk.

Bull case (what the Street likes):

• Secular tailwind from higher transplant volumes, stricter OPO metrics and the push toward better utilization of marginal organs, all of which favor specialized logistics and clinical partners.
• Two-segment platform (Logistics + Clinical) that deepens relationships with hospitals and creates cross-selling opportunities, with clinical services carrying higher structural margins.
• Clean balance sheet with very low leverage, 61M USD cash and an undrawn JP Morgan facility that can fund bolt-on acquisitions without immediate heavy equity dilution.
• Valuation that still embeds skepticism: at ~1.7× sales and a double-digit discount to analyst targets, there is room for re-rating if free cash flow inflects in 2026 as guided.

Bear case (what the skeptics focus on):

• Free cash flow has been negative, and the bridge between Adjusted EBITDA and cash is not yet proven; guidance assumes a strong improvement that may be difficult to deliver in a choppy macro environment.
• Integration risk around Keystone and any future acquisitions: if clinical margins disappoint or turnover among specialized staff rises, the whole thesis around higher-margin services comes under pressure.
• Regulatory and reimbursement risk: a change in how transplant-related services are paid, or tougher rules on outsourcing, could compress pricing power.
• High beta, elevated short interest and an SPAC heritage make the stock vulnerable to violent drawdowns on any negative headline, independently of long-term fundamentals.

The Merlintrader Health Score of 3.5/5 essentially reflects this balance: a credible structural story with real assets and customers, but still in the “prove-it” phase on free cash flow and integration.

Strata is not a biotech with binary trial outcomes, but it is still a high-beta, execution-sensitive story with a balance of attractive structural tailwinds and very real operational risks.

On the positive side, the transplant ecosystem is structurally growing: regulatory reforms are pushing for more transplants, higher utilization of medically complex organs, and stricter performance metrics for OPOs. Strata positions itself exactly at this intersection, offering hospitals and OPOs an outsourced, integrated solution for organ recovery and logistics. The Keystone acquisition deepens the moat by adding perfusion and cardiovascular clinical services, while the JP Morgan facility gives the company dry powder for further bolt-on deals.

On the risk side, investors must watch a few red flags. First, free cash flow has been negative and remains the key swing factor; guidance assumes a sharp inflection in 2026, which will require disciplined execution and no major negative surprises on legal or transaction costs. Second, integration risk is non-trivial: Keystone must be integrated not only operationally but also culturally, while maintaining clinical quality and margins. Third, regulatory risk cuts both ways – a supportive environment today could become more demanding in terms of pricing or quality metrics tomorrow.

In a constructive scenario, Strata executes on its 2026 guidance, converts Adjusted EBITDA into meaningful free cash flow, and uses the JP Morgan facility plus cash generation to consolidate more perfusion/logistics targets. In that case, the stock could gradually re-rate towards the current analyst target range as the market gains confidence in the business model. In a less benign scenario, delays in integration, weaker-than-expected margins or additional non-recurring costs could erode cash and force a more dilutive or leveraged path to growth.

Overall, SRTA sits in the middle of the Merlintrader Health Score range: not a distressed balance sheet nor a fully de-risked compounder. For investors who follow the broader “Run-Up” logic, this is more of a structural, execution-driven compounder in a regulated niche than a binary catalyst play. The focus should remain on quarterly cash-flow conversion, integration milestones for Keystone and the pace and terms of any future acquisitions.